

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
Office of Tissues and Advanced Therapies (OTAT)
Cellular, Tissue and Gene Therapies (CTGT)
Advisory Committee Meeting
April 15, 2021

DRAFT AGENDA

TOPIC SUMMARY

On April 15, 2021, the committee will discuss biologics license application (BLA) 125734 for donislecel (purified allogeneic deceased donor pancreas derived Islets of Langerhans). The applicant, CellTrans, Inc., has requested an indication for the “treatment of brittle Type I diabetes mellitus (T1D)”. The morning session will discuss issues related to the characterization and critical quality attributes of donislecel as they relate to product comparability in the context of consistent product quality and clinical effectiveness. The afternoon session will discuss results from the clinical trials included in BLA 125734.

10:00 a.m.	Opening Remarks: Call to Order and Welcome	Chairperson, Lisa Butterfield, Ph.D. (5 min) Vice-President, PICI Research Center University of California, San Francisco
	Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement	Jarrod Collier, M.S. (15 min) Designated Federal Officer
10:20 a.m.	FDA Opening Remarks	Wilson W. Bryan, M.D. (5 min) Director Office of Tissues and Advanced Therapies (OTAT), CBER
10:25 a.m.	Assessment of Islet Quality Pre-Transplant	Klearchos Papas, Ph.D. (25 min) Director Institute for Cellular Transplantation University of Arizona
	Q and A (15 min)	

Islet Cell – Chemistry, Manufacturing, and Control (CMC)

11:05 a.m.	APPLICANT PRESENTATIONS	CellTrans, Inc. (20 min)
	Introduction and Manufacturing Process	James McGarrigle, Ph.D.
	Potency and Purity Assays and Relationships to Clinical Outcomes	José Oberholzer, M.D., M.H.C.M., F.A.C.S.

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)**

*Office of Tissues and Advanced Therapies (OTAT) Advisory Committee Meeting
April 15, 2021*

DRAFT AGENDA (cont.)

11:25 a.m.	FDA PRESENTATION	Sukhanya Jayachandra, Ph.D (20 min) Cell Therapy Branch Division of Cellular and Gene Therapies (DCGT) OTAT, CBER
11:45 a.m.	CMC Clarifying Questions to Presenters	(15 min)
12:00 p.m.	CMC Questions to the Committee/Committee Discussion	(60 min)
1:00 p.m.	LUNCH BREAK	(45 min)
1:45 p.m.	OPEN PUBLIC HEARING	(60 min)
Clinical		
2:45 p.m.	FDA Clinical Introductory Remarks	Elizabeth Hart, M.D. (5 min) Branch Chief Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT) OTAT, CBER
2:50 p.m.	APPLICANT PRESENTATION	CellTrans, Inc. (45 min)
	Introduction, Agenda, Executive Summary	José Oberholzer, M.D., M.H.C.M., F.A.C.S.
	Introduction to Diabetes and Unmet Clinical Need	Betul Hatipoglu, M.D.
	Introduction to Islet Cell Transplantation	James Shapiro, M.D., Ph.D., F.R.C.S.(Eng), F.R.C.S.C., M.S.M., F.C.A.H.S.
	Efficacy, Safety, and Risk-Benefit Assessment	José Oberholzer, M.D., M.H.C.M., F.A.C.S.
3:35 p.m.	BREAK	(10 min)
3:45 p.m.	FDA PRESENTATION Clinical Considerations	Patricia Beaston, M.D., Ph.D. (45 min) Medical Officer DCEPT, OTAT, CBER

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)

Office of Tissues and Advanced Therapies (OTAT) Advisory Committee Meeting
April 15, 2021

DRAFT AGENDA (cont.)

4:30 p.m.	Clarifying Questions to Presenters	(30 min)
5:00 p.m.	Questions to the Committee/Committee Discussion/Voting/Member Remarks	(60 min)
6:00 p.m.	CLOSING REMARKS	Dr. Peter Marks Director, CBER
	ADJOURNMENT	Jarrold Collier, M.S. Designated Federal Officer